Drugs / Guaraná
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07151391 | Sep 2025 → Sep 2027 expected | female reproductive organ cancer, neuroendocrine neoplasm | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT01043913 | Feb 2008 → Sep 2009 | breast neoplasm | Faculdade de Medicina do ABC | Completed | Missed primary |
| Phase 2 | NCT00615316 | Dec 2006 → Jun 2007 | — | Faculdade de Medicina do ABC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Guaraná | “Guaraná, a native plant from the Amazon, might improve chemotherapy-induced fatigue in breast cancer patients undergoing treatment.” NCT01043913 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Guaraná (Paullinia cupana) has been used medicinally for centuries.” PMID 19388866 ↗ Apr 2009 |
| Route | Oral | “Guaraná 50mg or a placebo p.o. q12 for 21 days” NCT01043913 ↗ |